{"name":"Aeterna Zentaris","slug":"aeterna","ticker":"AEZS","exchange":"NASDAQ","domain":"aezsinc.com","description":"Aeterna Zentaris is a specialty pharmaceutical company focused on endocrinology. The company's top drugs include Macrilen, a growth hormone-stimulating peptide, and Macimorelin, a growth hormone-releasing hormone agonist. Aeterna Zentaris is positioned in the market with a focus on rare endocrine disorders.","hq":"Charleston, SC","founded":0,"employees":"N/A","ceo":"Klaus Paulini","sector":"Specialty Pharma / Endocrinology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":10000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2017-01-01","label":"Macrilen first approved","drug":"Macrilen","drugSlug":"macimorelin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Macrilen patent cliff ($10.0M at risk)","drug":"Macrilen","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Macimorelin patent cliff ($20.0M at risk)","drug":"Macimorelin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"AEZS-108 / zoptarelin doxorubicin","genericName":"AEZS-108 / zoptarelin doxorubicin","slug":"aezs-108-zoptarelin-doxorubicin","indication":"Ovarian cancer","status":"phase_3"},{"name":"AEZS-130 (formerly ARD-07)","genericName":"AEZS-130 (formerly ARD-07)","slug":"aezs-130-formerly-ard-07","indication":"Castration-resistant prostate cancer (CRPC)","status":"phase_3"},{"name":"Cetrorelix 78+78","genericName":"Cetrorelix 78+78","slug":"cetrorelix-78-78","indication":"Hormone receptor-positive breast cancer (in combination with endocrine therapy)","status":"phase_3"},{"name":"Cetrorelix Pamoate","genericName":"Cetrorelix Pamoate","slug":"cetrorelix-pamoate","indication":"Prostate cancer (hormone-dependent)","status":"phase_3"},{"name":"shark cartilage extract AE-941","genericName":"shark cartilage extract AE-941","slug":"shark-cartilage-extract-ae-941","indication":"Metastatic colorectal cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"L-ARG+GHRH","genericName":"L-ARG+GHRH","slug":"l-arg-ghrh","indication":"Adult growth hormone deficiency","status":"phase_3"},{"name":"Macrilen","genericName":"MACIMORELIN","slug":"macimorelin","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"AEZS-108 / zoptarelin doxorubicin","genericName":"AEZS-108 / zoptarelin doxorubicin","slug":"aezs-108-zoptarelin-doxorubicin","phase":"phase_3","mechanism":"AEZS-108 is a conjugate of a GnRH agonist (zoptarelin) linked to the chemotherapy drug doxorubicin, designed to deliver cytotoxic payload selectively to GnRH receptor-expressing cancer cells.","indications":["Ovarian cancer","Endometrial cancer"],"catalyst":""},{"name":"AEZS-130 (formerly ARD-07)","genericName":"AEZS-130 (formerly ARD-07)","slug":"aezs-130-formerly-ard-07","phase":"phase_3","mechanism":"AEZS-130 is a selective androgen receptor (AR) antagonist that blocks androgen signaling in hormone-sensitive cancers.","indications":["Castration-resistant prostate cancer (CRPC)","Hormone-sensitive prostate cancer"],"catalyst":""},{"name":"Cetrorelix 78+78","genericName":"Cetrorelix 78+78","slug":"cetrorelix-78-78","phase":"phase_3","mechanism":"Cetrorelix is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone and follicle-stimulating hormone to inhibit ovarian steroid production.","indications":["Hormone receptor-positive breast cancer (in combination with endocrine therapy)","Ovarian cancer (hormone-sensitive)"],"catalyst":""},{"name":"Cetrorelix Pamoate","genericName":"Cetrorelix Pamoate","slug":"cetrorelix-pamoate","phase":"phase_3","mechanism":"Cetrorelix pamoate is a gonadotropin-releasing hormone (GnRH) antagonist that blocks GnRH receptors to suppress luteinizing hormone and follicle-stimulating hormone secretion.","indications":["Prostate cancer (hormone-dependent)","Ovarian suppression in assisted reproductive technology"],"catalyst":""},{"name":"L-ARG+GHRH","genericName":"L-ARG+GHRH","slug":"l-arg-ghrh","phase":"phase_3","mechanism":"L-arginine combined with growth hormone-releasing hormone (GHRH) stimulates endogenous growth hormone secretion to promote anabolic effects and tissue repair.","indications":["Adult growth hormone deficiency","Age-related growth hormone decline / somatopause"],"catalyst":""},{"name":"Macrilen","genericName":"MACIMORELIN","slug":"macimorelin","phase":"marketed","mechanism":"Macrilen works by binding to the growth hormone secretagogue receptor type 1, triggering a response that stimulates the release of growth hormone.","indications":[],"catalyst":""},{"name":"shark cartilage extract AE-941","genericName":"shark cartilage extract AE-941","slug":"shark-cartilage-extract-ae-941","phase":"phase_3","mechanism":"AE-941, a shark cartilage extract, is thought to inhibit angiogenesis.","indications":["Metastatic colorectal cancer"],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"regulatory","headline":"Aeterna Zentaris Announces FDA Approval of Macrilen for the Diagnosis of Adult Growth Hormone Deficiency","summary":"Aeterna Zentaris announced that the FDA has approved Macrilen for the diagnosis of adult growth hormone deficiency.","drugName":"Macrilen","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Aeterna Zentaris Reports Third Quarter 2023 Financial Results","summary":"Aeterna Zentaris reported its third quarter 2023 financial results, with revenue of $1.4 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1fZmpQeTJxTm1lY3ZtRVFVSml2Y0VmX0VMeUlKOHVsdjRsNzNrUjRoVGRrek5mbjFxLWNrdElOcXYzODRsQl9JT0FDYjM1TTNyczRCUV8xMTQ0ZUFZY3FR?oc=5","date":"2024-08-08","type":"pipeline","source":"ChartMill","summary":"AEZS Stock Price, Quote & Chart | AETERNA ZENTARIS INC (NASDAQ:AEZS) - ChartMill","headline":"AEZS Stock Price, Quote & Chart | AETERNA ZENTARIS INC (NASDAQ:AEZS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNYjFLUllYd3M3RzMzdlVrNzJDQ05rbGNhVjFVRjlyYkdqMk9UMTNIMWpFR3dBZllhNlBXSDhWS2dTbTFwS3o2UWNxblJ5RFRyMjhYVjYzejhWbUItclRQMU94bWFlVmphX1M5SDVXZkRTb0RBM3BQTXJ2emhucGczLXdocV9QMlFuRzJQUUJjbldkMHFKbU5FWWx2UXI1emVJWnhTLURHc3puM0xfVUZpWFF6X3dYb1NjTTRiTA?oc=5","date":"2024-08-07","type":"pipeline","source":"Fierce Pharma","summary":"Aeterna Zentaris not so eternal after all as biopharma rebrands to become ‘COSCIENS Biopharma’ - Fierce Pharma","headline":"Aeterna Zentaris not so eternal after all as biopharma rebrands to become ‘COSCIENS Biopharma’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOVlpNS2pBRThLV1k4SW1PM3F1dUVvR0hIQThCa1lDVmQ5NU84RTRmZ1pDdjdKZ2p2eUtSTk5GZGpldmZ4RGhDS2paTnRhak1tMnVxYm42eHAwNGUwMUxpLTRlUEo4UkVtYjBnTDJqdnNIQ1RJZFJCSGFYUXE5amltRVNOZER1TkRv?oc=5","date":"2024-08-06","type":"pipeline","source":"Yahoo Finance","summary":"Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc. - Yahoo Finance","headline":"Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOczdxRTZNUllVLXdLYWlHYzJaTlBXWGx5VG14NXNfMk8zZFRRLVpRM0d6MVNuYTctZ3lsRVAxSkwyUExkWEJPNmNHcXVhUkIxWHRuWGl5OVFZZ3puWlJzSUNjLUFWcXZreXc0RnhVaHRHaEtMbFJtREVGamFxc3lCbHZTTS1IVWhvUHljdzZiQkh6UWItdkktbm5uUURnYUFGOUdmQVU1THBhMENWS01JUTExWTh6b2twa01OTkxCbXM3ZkpCSUE?oc=5","date":"2024-06-03","type":"deal","source":"GlobeNewswire","summary":"Aeterna Zentaris and Ceapro Complete Merger Transaction - GlobeNewswire","headline":"Aeterna Zentaris and Ceapro Complete Merger Transaction","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQMVR6Rk1UUDc2eE9pY1k1aThLRC1TM08zNWg2RVFwQTRfdHNEQWxJR05FRThRN2ZnOVM0c2JHSHdKR0EzanpRdHB5b3ZxVVpQdnNkQ3JYVVA4ZG85SXlySkFJS1hiQjB3UmVFendZaVJwWkcwdGdHNGhYb3g3TVA2ZnBuZkZYQ2NZZHJFMFM0bXZ2NDRzR1JsUXRXbmtXT0pXbjZCaUhmbmM0NER6dU50N18yWWUtSWhsVXNMQWhSQVBfY05OdWtBZXRaeWJaZzRSZkw0TXRnZ25IY29sekdJZEhVSVNfc3gwanFKanNGY3dEVjVVamhqd2RMSnhmdWxyRHBFc2dR?oc=5","date":"2023-12-14","type":"deal","source":"GlobeNewswire","summary":"Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company - GlobeNewswire","headline":"Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPTjYtQ24wVVc2bFhMdlVSQTNvTHpJa0lBMWM2TlhCWllZNXoyUDBpSnpHRnZwbnl4ams2TmdHSnpobjZ0V2kxX01qZG9qOHZoVkxQUjJJejlJbVJYazktRDZ6QWsyVENleGEzNlJ4SVl6bF9wVWZXZ1dUNVNHZk4tMlFRS2tlUHpoZS1IakRGeFgxT2I5eTl4ckgyeV9TVFhldGFNMnU3Y1p2MVNWdXAzSVpORUtjR1RseFlKcTJfQmxha3ZyWnc?oc=5","date":"2021-05-11","type":"pipeline","source":"University of Sheffield","summary":"Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism - University of Sheffield","headline":"Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPOFN4UE1heWZPMFo4VGVLOThSb05YLWJWemxKb1R3VHFlSUc0SE1odFg5WWRnR1R0RjNkNldrcjhWUUx1dW96Mmc3UXVHdDY4M3JNdXJZQTFlYWg5czFQNHh4TjJkaGszZF9FT2YzRmNQNnlaaXYtdllxVDN1UWpPZFE3UVg3M2pQbG9XMWJkMkVhRU5CaGpFUnFEX3pHZzl6S0NZWWhxdmMxanlJUWg5NjhB?oc=5","date":"2017-12-23","type":"regulatory","source":"Medical Dialogues","summary":"FDA Approves new test of for Diagnosis of Adult Growth Hormone Deficiency - Medical Dialogues","headline":"FDA Approves new test of for Diagnosis of Adult Growth Hormone Deficiency","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOdnEzTGdPSlh4ck1xUEotUHZPZG9kOUEyREN6d1VJdUx5cUcyNXNqdlZBMUw1NGJvNHVUNGpHdDBCODB4YjhmQ1k2WmJfLVFTTlRfMk9GZUZNUV9HR0NBRnpqZXpFMG8xa2dXS3l0SzNjTlZ1QWhPMGZIUFE5UDNRUjVxeG83TlZWY1UzVGlKN3o0S3lGRTNBam14WFlOT0F1X2dWOGZtQXZsaEdNRlFrdmh1dmhSamlwbFE?oc=5","date":"2011-03-24","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Aeterna Zentaris Wins $1.5M from BMBF to Develop GPCR-Targeting Disorazol Z Conjugates - Genetic Engineering and Biotechnology News","headline":"Aeterna Zentaris Wins $1.5M from BMBF to Develop GPCR-Targeting Disorazol Z Conjugates","sentiment":"neutral"}],"patents":[{"drugName":"Macrilen","drugSlug":"macimorelin","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":10000000},{"drugName":"Macimorelin","drugSlug":"macimorelin","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":20000000}],"drugCount":7,"phaseCounts":{"phase_3":6,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Novo Nordisk","Pfizer","Eli Lilly"],"therapeuticFocus":["Endocrinology","Rare Diseases"],"financials":null,"yahoo":null}